Mark McHale

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Jianbiao Zhou, Jessie Yiying Quah, Yvonne Ng et al. · Haematologica · 2019 · 82 citations · Full text

Medicine, Oncology, Pharmacology +15

RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis

Kelsi Andrade, Jaime Fornetti, Ling Zhao et al. · Science Translational Medicine · 2017 · 68 citations · Full text

Medicine, Cancer Biology, Oncology +17

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Aflah Roohullah, Adam Cooper, Anna J. Lomax et al. · Investigational New Drugs · 2018 · 23 citations

Medicine, Pharmacokinetics, Pharmacology +14

Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.

Aaron C. Tan, Do‐Youn Oh, Yee Chao et al. · Journal of Clinical Oncology · 2019 · 14 citations

Medicine, Oncology, Pharmacology +14

Cooperative Learning in an Elementary Physical Education Program

Jimmy H. Ishee, Mark McHale · Journal of Physical Education Recreation & Dance · 2002 · 12 citations

Education, Elementary Education, Physical Education +9